239 related articles for article (PubMed ID: 38566201)
1. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
Ji G; Yang Q; Wang S; Yan X; Ou Q; Gong L; Zhao J; Zhou Y; Tian F; Lei J; Mu X; Wang J; Wang T; Wang X; Sun J; Zhang J; Jia C; Jiang T; Zhao MG; Lu Q
Genome Med; 2024 Apr; 16(1):49. PubMed ID: 38566201
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
3. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
[TBL] [Abstract][Full Text] [Related]
4. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.
Liu J; Chen H; Qiao G; Zhang JT; Zhang S; Zhu C; Chen Y; Tang J; Li W; Wang S; Tian H; Chen Z; Ma D; Tian J; Wu YL
Cancer Immunol Immunother; 2023 Apr; 72(4):881-893. PubMed ID: 36121452
[TBL] [Abstract][Full Text] [Related]
5. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma.
Wen J; Fang S; Hu Y; Xi M; Weng Z; Pan C; Luo K; Ling Y; Lai R; Xie X; Lin X; Lin T; Chen J; Liu Q; Fu J; Yang H
EBioMedicine; 2022 Dec; 86():104371. PubMed ID: 36434949
[TBL] [Abstract][Full Text] [Related]
6. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
Wu P; Zhang Z; Yuan Y; Zhang C; Zhang G; Xue L; Yang H; Wang L; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Xue Q; Sun N; He J
Int J Surg; 2022 Nov; 107():106960. PubMed ID: 36257585
[TBL] [Abstract][Full Text] [Related]
7. PES1 reduces CD8
Ma N; Hua R; Yang Y; Liu ZC; Pan J; Yu BY; Sun YF; Xie D; Wang Y; Li ZG
J Biomed Sci; 2023 Mar; 30(1):20. PubMed ID: 36959575
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial.
Chen X; Xu X; Wang D; Liu J; Sun J; Lu M; Wang R; Hui B; Li X; Zhou C; Wang M; Qiu T; Cui S; Sun N; Li Y; Wang F; Liu C; Shao Y; Luo J; Gu Y
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759013
[TBL] [Abstract][Full Text] [Related]
9. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
10. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
11. Single-cell transcriptomics reveals heterogeneity in esophageal squamous epithelial cells and constructs models for predicting patient prognosis and immunotherapy.
Li C; Song W; Zhang J; Luo Y
Front Immunol; 2023; 14():1322147. PubMed ID: 38098487
[TBL] [Abstract][Full Text] [Related]
12. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.
Yehan Z; Sheng Q; Hong Y; Jiayu L; Jun H; Juan J; Min S; Jiaxin Y; Shangzhi H; Yi W; Qifeng W; Xuefeng L; Wenwu H; Xueyan C; Yang L; Zongyao H
Front Immunol; 2024; 15():1312380. PubMed ID: 38726002
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma.
Qu J; Zhao Q; Yang L; Ping Y; Zhang K; Lei Q; Liu F; Zhang Y
Int Immunopharmacol; 2021 Jul; 96():107616. PubMed ID: 34162127
[TBL] [Abstract][Full Text] [Related]
14. High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.
Han D; Han Y; Guo W; Wei W; Yang S; Xiang J; Che J; Zhu L; Hang J; van den Ende T; van Laarhoven HWM; Li B; Ye Y; Li H
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38016720
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol.
Chen M; Huang Y; Zhang S; Zeng T; Huang G; Chen C; Zheng B
Trials; 2023 Aug; 24(1):554. PubMed ID: 37626367
[TBL] [Abstract][Full Text] [Related]
16. Single cell sequencing revealed the mechanism of PD-1 resistance affected by the expression profile of peripheral blood immune cells in ESCC.
Deng T; Wang H; Yang C; Zuo M; Ji Z; Bai M; Ning T; Liu R; Wang J; Ge S; Zhang L; Ba Y; Zhang H
Front Immunol; 2022; 13():1004345. PubMed ID: 36466860
[TBL] [Abstract][Full Text] [Related]
17. Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.
Liu Y
World J Gastroenterol; 2023 Sep; 29(34):5020-5037. PubMed ID: 37753366
[TBL] [Abstract][Full Text] [Related]
18. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
[TBL] [Abstract][Full Text] [Related]
19. Th1-involved immune infiltrates improve neoadjuvant chemoradiotherapy response of esophageal squamous cell carcinoma.
Yuan J; Weng Z; Tan Z; Luo K; Zhong J; Xie X; Qu C; Lin X; Yang H; Wen J; Fu J
Cancer Lett; 2023 Jan; 553():215959. PubMed ID: 36279981
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
